Telomir Pharmaceuticals announces preclinical findings on Telomir-1
Telomir Pharmaceuticals (TELO) announced preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a ...
TELO Study Shows Cancer-Related Breakthrough
TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...
Hosted on MSN25d
TELO Again Announces Breakthrough Results
Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical ... a preclinical study of Telomir-1 on human retinal cell lines. Data from the test showed the ability of Telomir ...
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
This groundbreaking finding suggests that Telomir-1 may selectively benefit healthy cells while suppressing malignant growth, challenging the assumption that telomere-elongating drugs inherently ...
Sacramento Bee4d
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
Telomir-1 has already been shown in multiple human cell lines to successfully elongate ... Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical stage pharmaceutical company seeking ...